ATRO Medical is an innovative medical device company that was founded in 2016. The first product under development is the Trammpolin® meniscus prosthesis. The meniscus is an important shock absorber in the knee joint. Damage and wear of the meniscus are important causes of osteoarthritis of the knee. Trammpolin® intends to replace the damaged meniscus, with the aim of restoring the shock absorbing function of the meniscus by acting as a joint spacer.

The company is addressing a large unmet medical need, as the number of patients with knee pain caused by a meniscectomy increase. These patients gradually develop osteoarthritis, resulting in pain and reduced mobility. Current treatment options for these patients are limited with distinct drawbacks. The Trammpolin® meniscus prosthesis aims to provide a cost-­effective solution for meniscus replacements and to fill the gap in treatment options between meniscus tear surgical repair and total knee replacement.

We invested in Atro Medical from our Evergreen Fund.